LUYE PHARMA (02186) announced that on January 26, 2026, Shenzhen LUYE, Nanjing Xinshi, Nanjing Xin'an, Ningbo Xinda, and Nanjing LUYE entered into a capital injection agreement. Under this agreement, Nanjing Xin'an and Ningbo Xinda agreed to provide additional capital to Nanjing LUYE, totaling RMB 285 million.

Immediately following the completion of the capital injection, Nanjing LUYE will be held 70.01%, 23.34%, 4.32%, and 2.33% by Shenzhen LUYE, Nanjing Xinshi, Nanjing Xin'an, and Ningbo Xinda, respectively. In connection with the capital injection by Nanjing Xin'an and Ningbo Xinda into Nanjing LUYE, the Group has entered into a series of further transactions.

Pursuant to the Nanjing LUYE Equity Option Agreement, Yantai LUYE has the right to require each Xinda subscriber to sell their respective equity interests in Nanjing LUYE to Yantai LUYE. According to the Nanjing LUYE Equity Option Agreement, each Xinda subscriber has the right to require Yantai LUYE to repurchase their respective equity interests in Nanjing LUYE upon the occurrence of certain events.

As of the date of this announcement, Nanjing LUYE is held 75% and 25% by Shenzhen LUYE and Nanjing Xinshi, respectively. Nanjing LUYE and its subsidiaries are primarily engaged in the production and sales of pharmaceutical products, with a focus on the field of oncology therapeutics.

Both Yantai LUYE and Shenzhen LUYE are wholly-owned subsidiaries of the Company. Yantai LUYE and Shenzhen LUYE are each primarily engaged in the business of investment holding.